
==== Front
Eur J Pediatr
Eur J Pediatr
European Journal of Pediatrics
0340-6199
1432-1076
Springer Berlin Heidelberg Berlin/Heidelberg

39023645
5683
10.1007/s00431-024-05683-4
Research
Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohort
http://orcid.org/0000-0002-1836-3745
Mitrova Katarina katarina.mitrova@fnmotol.cz

12
http://orcid.org/0000-0003-1593-5899
Cerna Karin 13
http://orcid.org/0000-0002-8024-1626
Zdychyncova Kristyna 1
http://orcid.org/0000-0002-0315-8845
Pipek Barbora 45
http://orcid.org/0000-0001-6636-9335
Svikova Jana 6
Minarikova Petra 7
Adamcova Miroslava 8
http://orcid.org/0000-0003-1131-2475
David Jan 9
http://orcid.org/0000-0002-1463-3840
Lukas Milan 1
http://orcid.org/0000-0002-6090-3522
Duricova Dana 110
1 IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic
2 https://ror.org/024d6js02 grid.4491.8 0000 0004 1937 116X Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06 Prague, Czech Republic
3 grid.485488.d GENNET s.r.o., Prague, Czech Republic
4 Digestive Diseases Centre, Hospital AGEL Vitkovice, Ostrava, Czech Republic
5 grid.10979.36 0000 0001 1245 3953 2nd Department of Internal Medicine Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
6 https://ror.org/00cybb798 grid.500411.1 Department of Internal Medicine, Jihlava Hospital, Jihlava, Czech Republic
7 https://ror.org/03a8sgj63 grid.413760.7 0000 0000 8694 9188 Department of Medicine 1st Faculty of Medicine Charles University and Military Hospital, Military University Hospital Prague, Prague, Czech Republic
8 Private practice of General Pediatrician, Prague, Czech Republic
9 https://ror.org/04sg4ka71 grid.412819.7 0000 0004 0611 1895 Department of Children and Adolescents, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
10 https://ror.org/024d6js02 grid.4491.8 0000 0004 1937 116X Department of Pharmacology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Communicated by Gregorio Milani

18 7 2024
18 7 2024
2024
183 10 42434251
5 3 2024
2 7 2024
5 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Evidence on serological responses to vaccination in children exposed to ustekinumab (UST) or vedolizumab (VDZ) in utero is lacking. This multicentre prospective study aimed to assess the impact of prenatal exposure to UST or VDZ due to maternal inflammatory bowel disease (IBD) on serological responses to vaccination and other immunological parameters in exposed children. Children aged ≥ 1 year who were exposed in utero to UST or VDZ and completed at least 1-year of mandatory vaccination were included. We assessed the serological response to vaccination (non-live: tetanus, diphtheria, and Haemophilus influenzae B; live: mumps, rubella, and measles), whole blood count, and immunoglobulin levels. The control group comprised unexposed children born to mothers without IBD. A total of 23 children (median age, 25 months) exposed to UST (n = 13) or VDZ (n = 10) and 10 controls (median age, 37 months) were included. The serological response to vaccination was comparable between the UST and VDZ groups and controls, with an adequate serological response rate of ≥ 80%. Only children exposed to UST showed a slightly reduced serological response to mumps (67% vs. 86% in controls), whereas all children exposed to VDZ showed an adequate response. The majority of the exposed children had normal levels of individual immunoglobulin classes, similar to the controls. No severe pathology was observed in any of the children.

Conclusion: Despite the limited sample size, our findings suggest that in utero exposure to VDZ or UST does not significantly impair the vaccine response or broader immunological parameters in exposed children.

What is known:

• Treatment with anti-TNF inhibitors during pregnancy does not appear to affect serologic response to vaccination in exposed children.

• Evidence on the efficacy of vaccination in children exposed to ustekinumab or vedolizumab in utero is almost lacking.

What is new:

• Our findings suggest that in utero exposure to ustekinumab or vedolizumab does not significantly affect the serological responses to common childhood non-live (tetanus, Haemophilus influenzae B, diphtheria) and live vaccines (measles, mumps, rubella).

• No major adverse effects on overall immunological health were observed in children exposed in utero to ustekinumab or vedolizumab.

	

Supplementary information

The online version contains supplementary material available at 10.1007/s00431-024-05683-4.

Keywords

Biologic treatment
Prenatal exposure
Vaccination
Pregnancy
Inflammatory bowel disease
Charles UniversityOpen access publishing supported by the National Technical Library in Prague.

issue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

A significant proportion of women with inflammatory bowel disease (IBD) are diagnosed at childbearing age, necessitating consideration of the impact of medication during pregnancy. Proper disease control appears to be the most important factor for favourable pregnancy outcomes [1]. This may require intensive anti-inflammatory therapy, including biologic treatment, which has been a matter of concern regarding its safety on the immune system of prenatally exposed children, including adequacy of response to vaccination.

According to published evidence, treatment with anti-TNF inhibitors during pregnancy does not appear to affect the serological response to vaccination in exposed children [2–6]. However, the evidence on efficacy of vaccination given to children exposed to ustekinumab or vedolizumab in utero is sparse. Although data on the serological response to vaccination (except for the oral vaccine in the case of vedolizumab) in adult patients with immune-mediated diseases on vedolizumab or ustekinumab have been favourable [7–9], the results cannot be automatically extrapolated from the adult population to children exposed to these biologics in utero.

The primary objective of this multicentre prospective study was to evaluate the serological response to vaccination in children exposed to ustekinumab or vedolizumab in utero. The secondary objective was to evaluate other immune system parameters in the exposed children.

Methods

Study population

This study is a “sub-study” of prospective multicentre project focused on the safety of biologic therapy during pregnancy in women with IBD, including maternal, pregnancy, and children outcome [10]. Women with IBD and their children treated with ustekinumab or vedolizumab during pregnancy at three IBD centres were offered to participate in this study if they met the following criteria: (i) singleton pregnancy ended in live birth over 1 year ago and (ii) children who had completed at least 1 year of mandatory vaccination.

The control group consisted of children of healthy mothers unexposed to biologic therapy recruited either in collaboration with the general paediatrician or were the offspring of medical staff and their relatives. The children in the control group were selected within the age range of the exposed children.

The mandatory vaccination protocol consisted of a hexavalent non-live vaccine (hepatitis B, Haemophilus influenzae B, diphtheria, tetanus, pertussis, and inactivated polio) with a standard 3-dose schedule administered within the first year of age. Mandatory vaccination with live vaccines (mumps, rubella, and measles) begins at 13 months of age, with a second dose administered at 5–6 years of age.

Data collection

Clinical and demographic data of women with IBD, details of biologic and concomitant therapy during pregnancy, and disease activity were obtained from the patients’ medical files by treating gastroenterologists. Information on the perinatal period (gestational age at birth, mode of delivery, birth weight, perinatal complications, and congenital malformation), breastfeeding, and safety of vaccination of both the exposed and control children was obtained from the mother and/or treating paediatrician. A predefined questionnaire was used to collect all the data.

Laboratory analysis

A single blood sample was collected from each exposed and control child at the time of recruitment. Blood samples were analysed using standard laboratory methods. Complete blood count and parameters of humoral immunity, including serologic response to vaccination (non-live vaccines: tetanus, Haemophilus influenzae B, diphtheria, and live vaccines: measles, mumps, rubella) and measurement of serum levels of immunoglobulins (IgG, IgA, IgM, and IgE) were evaluated. Serologic response to vaccination was assessed if ≥ 3 doses of non-live vaccine and ≥ 1 dose of live vaccine were administered, and were considered adequate or inadequate according to the laboratory range (Supplementary Table 1).

Cord plasma from exposed children was analysed for ustekinumab or vedolizumab concentrations as a standard of care at the included centres, as previously described [10]. Drug levels were measured using the Ustekinumab ELISA mAb-based assay [IG-AB121] or Vedolizumab ELISA mAb-based assay [IG-AB116], both manufactured by ImmunoGuide, AybayTech Biotechnology.

Statistical analysis

Standard descriptive statistics were used, such as absolute numbers and percentages for categorical data, and medians (ranges) for continuous data. Comparisons between the groups were performed using Fisher’s exact test or the Mann-Whitney test. A general linear regression model was used to adjust for age at the time of blood sampling. p-value < 0.05 was considered statistically significant. Statistical analysis was performed using the SPSS software [version 17.0, Chicago, Il., USA].

Results

Forty-seven female patients with forty-nine pregnancies (28 exposed to ustekinumab and 21 exposed to vedolizumab) and children who fulfilled the inclusion criteria were invited to participate in this study. Of these, 23 (49%) women with a total of 24 children agreed to participate. In one child, the blood sample was unsuccessful due to the child's unwillingness to cooperate with blood collection, leaving 23 children for inclusion (13 exposed to ustekinumab and 10 to vedolizumab) (Supplementary Fig. 1). The remaining women who refused to participate in the study either did not want to stress their children with vein punctures or were not interested in the project because of time constraints. The control group consisted of ten unexposed children born to healthy mothers.

The clinical and demographic characteristics of the mothers with IBD and the control mothers are shown in Table 1. All but one woman treated with ustekinumab had Crohn’s disease, whilst the majority (60%) of females treated with vedolizumab had ulcerative colitis. Most women in both groups continued treatment in the third trimester (85% and 80% in the ustekinumab and vedolizumab groups, respectively). Approximately one-third of the patients in both groups were on concomitant thiopurines, and 40% of the women (n = 4) receiving vedolizumab also received systemic corticosteroids. In three women, corticosteroids were administered throughout pregnancy (dose 2, 20 mg daily), whilst the fourth patient received high-dose steroids with subsequent tapering between gestational weeks 16 and 26 because of relapse of her ulcerative colitis. The rate of steroid exposure reflects the fact that half of the women on vedolizumab had active disease at any time during pregnancy. Table 1 Clinical and demographic characteristics of mothers

	UST
(n = 13)	VDZ
(n = 10)	Con
(n = 10)	p-value
UST vs. Con	p-value
VDZ vs. Con	
Age at delivery (years)*	37.2 (21–39)	32 (26–38)	33 (28–39)	0.61	0.50	
Smoking during pregnancy (%)	1 (7.7)	0	0	-	-	
Mode of delivery (%)				0.67	0.65	
  Vaginal	7 (54)	5 (50)	7 (70)			
  Caesarean section	6 (46)	5 (50)	3 (30)			
Type of IBD (%)			-	-	-	
  CD	12 (92)	4 (40)				
  UC	1 (7.7)	6 (60)				
Disease duration (years)*	11.3 (4.0–22)	12.1 (8.9–20)	-	-	-	
CD disease localization# (%)			-	-	-	
  Ileal	4 (33)	-				
  Colonic	3 (25)	-				
  Ileocolonic	5 (42)	4 (100)				
  Upper	2 (17)	2 (50)				
CD disease behaviour# (%)			-	-	-	
  Inflammatory	10 (83)	3 (75)				
  Structuring	-	1 (25)				
  Penetrating	3 (17)	-				
CD—perianal disease# (%)	2 (17)	2 (50)				
UC extension# (%)			-	-	-	
  Proctitis	-	-				
  Left-sided	1 (100)	-				
  Extensive	-	6 (100)				
Previous intestinal surgery (%)	3 (23)	1 (10)	-	-	-	
Concomitant therapy (%)			-	-	-	
  None	8 (62)	5 (50)				
  Systemic steroids	-	4 (40)				
  Thiopurines	5 (39)	3 (30)				
Disease activity			-	-	-	
  Active**	1 (7.7)	5 (50)				
  Remission	12 (92)	5 (50)				
*Median (range); **any time during pregnancy; CD, Crohn’s disease; UC, ulcerative colitis; UST, ustekinumab; VDZ, vedolizumab; Con, controls

#Montreal classification

The median ages at blood sampling of the exposed and control children were 25 months (12.8–50.3) and 37.2 months (13.8–57.7), respectively. All but one child in the vedolizumab-treated group were born at term. In this case, the pregnancy was terminated prematurely at 26 weeks of gestation by caesarean section because of severe progressive preeclampsia and pathological placental blood flow. The perinatal data of the exposed and control infants are presented in Table 2. In 12 (92%) children exposed to ustekinumab cord plasma levels of the drug were available with a median level of 11.8 mg/l (0.4–30). The cord plasma levels of vedolizumab were measured in 7 (70%) children with a median level of 5.3 mg/l (1.1–21.3). Table 2 Birth outcomes

	UST
(n = 13)	VDZ
(n = 10)	Con
(n = 10)	p-value
UST vs. Con	p-value
VDZ vs. Con	
Gestational week of delivery*	39 (37–41)	38.5 (26–41)	39.5 (37–42)	0.61	0.46	
Preterm birth (%)	0	1 (10)	0	-	-	
Birth weight (grammes)*	3400 (2460–4000)	3075 (650–3755)	3405 (2410–3870)	0.62	0.50	
Low birth weight (%)	1 (7.7)	2 (20)	2 (20)	0.56	1.00	
Congenital malformation (%)	2 (15)

-Hydrocele

-Mild hip dysplasia

	2 (20)

-Cleft lip**

-Hypoplasia of kidney

	1 (10)

-Hypospadias

	1.00	1.00	
Breastfeeding	
   > 2 weeks (%)	11 (85)	9 (90)	10 (100)	1.00	1.00	
  Length (months) *	12.5 (1–17)	6 (1–15)	7 (2–14)	0.89	0.94	
*Median (range); **mother had symptomatic SARS-CoV-2 infection during the 1st trimester

UST, ustekinumab; VDZ, vedolizumab; Con, controls

Serologic response to vaccination

All but one premature child received vaccination according to the national vaccination schedule [11]. In this case, the vaccination schedule was adjusted based on the biological age of the child.

The serological response to non-live vaccination was considered adequate in ≥ 80% of children exposed to ustekinumab or vedolizumab and was comparable to that of controls (Fig. 1).Fig. 1 Proportion of children with adequate serologic response to vaccination: a non-live vaccines; b live vaccines. UST, ustekinumab; VDZ, vedolizumab; * ≥ 0.15 mg/L cut-off for post-vaccination seroprotection; ** > 1 mg/L cut-off for long-term post-vaccination seroprotection

Two children with ustekinumab exposure showed an inadequate response to Haemophilus influenzae vaccination. Both children were born at term, with the last administration of the drug at gestational weeks 27 and 30 and corresponding cord drug levels of 2.8 mg/l and 13 mg/l, respectively. The mother of one child was treated with concomitant thiopurines during pregnancy. However, when assessing long term post-vaccination protection against Haemophilus influenzae using a higher cut-off value (> 1.00 mg/L), a numerically lower response rate was observed, with 39% in ustekinumab group and 40% in vedolizumab group versus 67% in healthy controls (compared to controls: p = 0.39 for ustekinumab; p = 0.37 for vedolizumab).

With vedolizumab, two children (born at term) had insufficient antibody responses to diphtheria. In these children, the last dose of the biologic was administered at weeks 28 and 37 of gestation, resulting in cord blood levels of 1.4 mg/l and 10.4 mg/l, respectively. One child was exposed in utero to concomitant thiopurines and the other was exposed to corticosteroids.

Live vaccines resulted in an adequate serological response in ≥ 80% of the exposed children, which was comparable to that of the control group, except for mumps with numerically lower response rate in children exposed to ustekinumab (67% vs. 88%, p = 0.58) (Fig. 1). The mothers of these three children were treated with ustekinumab monotherapy in all three trimesters (the last dose at gestational week 28–35) and delivered at term. In two children, cord blood was available with drug levels of 1.5 mg/l and 10.3 mg/l, respectively.

Adjustment for age at blood sampling did not reveal any significant differences in the serologic response to vaccination between the control and either exposed groups, both for non-live and live vaccines (Supplementary Table 2).

Safety of vaccination

No clinically relevant adverse reactions to live or non-live vaccinations were observed in either group.

Other immunological parameters

Immunoglobulin levels

Most of the exposed children had normal levels of immunoglobulin classes, and none of the children had severe deficiencies. Three (23%) children exposed to ustekinumab had lower immunoglobulin levels (below the stated laboratory cut-offs for the normal range): three had lower IgA levels (0.20 g/l, 0.31 g/l [cut-off 0.33]; 0.5 g/l [cut-off 0.66]), whilst one had lower IgG (4.69 g/l, cut-off 5.53) and IgM levels (0.36 g/l, cut-off 0.47). Serologic response to vaccination in this child was adequate for diphtheria and tetanus and inadequate for haemophilus. Regarding vedolizumab, one child had lower levels of IgA (< 0.25 g/l, cut-off 0.33), whereas the other child with premature delivery had lower levels of IgA (0.12 g/l, cut-off 0.33), IgG (3.15 g/l, cut-off 5.53), and IgM (0.39 g/l, cut-off 0.47). Despite this, the child developed seroprotective antibodies against all non-live vaccines. In the control group, two children had lower levels of immunoglobulins, one in the IgA and the other in the IgG class. Both children showed an adequate response to the vaccination. Elevated levels of IgE were measured in one and two children exposed to ustekinumab and vedolizumab, respectively, and in one control child. Table 3 displays the serologic response to non-live vaccination with respect to immunoglobulin levels. Table 3 Proportion of children with seroprotective antibody titres to non-live vaccines stratified by immunoglobulin (Ig) levels

Ustekinumab

n (%)

	Low Ig#

n = 3 (23.1)

IgA + IgG + IgM: n = 1; IgA: n = 2

	Normal Ig

n = 10 (76.9)

-

	
Cord drug levels (mg/l)	n = 3: 0.4; 13.0; 13.2	n = 9: median 2.8 (range 1.5–30)	
Seroprotective titres (%)	
  Diphtheria	3/3 (100)	10/10 (100)	
  Tetanus	3/3 (100)	10/10 (100)	
  HiB ≥ 0.15	2/3 (66.7)	9/10 (90)	
  HiB > 1.00	1/3 (33.3)	4/10 (40)	
Vedolizumab

n (%)

	Low Ig#

n = 2 (20)

IgA + IgG + IgM: n = 1; IgA: n = 1

	Normal Ig

n = 8 (80)

-

	
Cord drug levels (mg/l)	n = 1: 21.3	n = 6: median 3.6 (range 1.1–10.4)	
Seroprotective titres	
  Diphtheria	2/2 (100)	6/8 (75)	
  Tetanus	2/2 (100)	8/8 (100)	
  HiB ≥ 0.15	2/2 (100)	8/8 (100)	
  HiB > 1.00	0	4/8 (50)	
Controls*

n (%)

	Low Ig

n = 2 (20)

IgA: n = 1; IgG: n = 1

	Normal Ig

n = 7 (70)

-

	
Seroprotective titres	
  Diphtheria	2/2 (100)	4/6 (66.7)	
  Tetanus	2/2 (100)	7/7 (100)	
  HiB ≥ 0.15**	2/2 (100)	6/6 (100)	
  HiB > 1.00**	1/2 (50)	5/6 (83.3)	
HiB, Haemophilus influenzae B

#Low Ig, below the normal laboratory range

*1 child did not have analyses of immunoglobulin levels

** ≥ 0.15 mg/L cut-off for post-vaccination seroprotection; > 1 mg/L cut-off for long-term post-vaccination seroprotection

Blood count

One child 26 months old who was exposed to ustekinumab monotherapy had an elevated platelet count (606 × 109/L) with no other pathology in the blood count. No clinically relevant abnormalities were found in either the exposed or control groups.

Discussion

This multicentre prospective study provides crucial insights into the immunological safety of ustekinumab and vedolizumab during pregnancy. Our data demonstrate that in utero exposure to ustekinumab or vedolizumab does not significantly diminish serological responses to routine childhood vaccinations. The adequate immunological responses observed in our cohort suggests that these biologics, when used during pregnancy, do not adversely affect the developing immune system of the foetus in a clinically significant manner.

Patients with IBD receiving immunosuppressive and/or biologic (anti-TNF) therapy have been reported to have an impaired post-vaccination serologic response to several vaccines [12–16]. Therefore, there have been concerns regarding the adequacy of serologic response to vaccination in children exposed to biologic preparations in utero. Nevertheless, several previous studies have demonstrated adequate serological responses to vaccination in children with prenatal exposure to anti-TNF preparations [3, 6].

However, in the era of newer biologics with different mechanisms of action (e.g., ustekinumab and vedolizumab), new safety concerns have arisen [10, 17–25].

Evidence from studies in adult patients with IBD suggests that vaccination is safe and effective in patients treated with vedolizumab or ustekinumab (except for oral vaccines in vedolizumab) [7–9]. However, these data cannot be automatically extrapolated to children with prenatal exposure to these agents. The main reason for this is the immaturity of their immune system, which is quite different and still develops during the first years of life and could potentially be affected by drug exposure. It is known that ustekinumab can cross the placenta with a transfer pattern similar to that described for anti-TNF agents, but its postnatal clearance seems to be faster (median of 9 weeks, complete by 20 weeks after birth) and even faster for vedolizumab (mean of 3.8 weeks, complete by 6 months) [25, 26]. This may indicate a lower impact of ustekinumab and vedolizumab on serological post-vaccination response. However, it must be kept in mind that the serologic response to vaccination and other immune system functions may be influenced by the drug’s impact on developing the immune system during the antenatal period, and not only by the presence of drug levels after birth. To the best of our knowledge, the only evidence on the immune response to vaccination in children exposed to new biologics comes from a recent study by Beaulieu et al., who reported a normal antibody response to Haemophilus influenzae B and tetanus vaccination in two individuals exposed in utero to ustekinumab and one to vedolizumab [4]. Our study confirms this finding in a larger group of children. The majority of our children (≥ 80%) had adequate responses to both non-live (diphtheria, tetanus, and Haemophilus influenzae) and live (measles, mumps, and rubella) vaccines, as observed in the control group. This was true for all but two vaccines: Haemophilus influenzae and mumps.

For Haemophilus influenzae, using a higher cut-off value (> 1.00 mg/L, reflecting long-term protection), an adequate serologic response was observed in only approximately 40% of exposed children and 67% of healthy controls. However, using a lower cut-off value (≥ 0.15 mg/L), which is commonly used in other studies to assess post-vaccination seroprotection against Haemophilus influenzae, an adequate response was observed in 85% of children exposed to ustekinumab and 100% of children exposed to vedolizumab or the control group. Currently, it is not clear which cut-offs are appropriate, as different cut-offs have been used in studies assessing serological response to this vaccine [3, 27–30]. Considering the potential risk factors for low serologic response after HiB vaccination (using a higher cut-off) in our cohort, such as maternal disease activity during pregnancy and concomitant corticosteroid or thiopurine use, no such signal was observed (data not shown). Of note, our previous study and the PIANO study of children with anti-TNF exposure in utero also demonstrated a lower serologic response to Haemophilus vaccine (adequate seroprotection below 75%), but this was also the case in the control group of unexposed children [3, 4]. We can only speculate whether the type of vaccine may also play a role, as the stimulation of the immune system may differ between vaccines.

A somewhat lower rate of adequate serology was also observed after mumps vaccination in the ustekinumab group. Most probably, this finding just reflects the limited sample size and further studies are needed to confirm this.

We did not find any pathology in the blood count, except for one child with significant thrombocytosis in the ustekinumab group. When basic immunological parameters, such as total serum immunoglobulin levels, were evaluated, no clinically significant pathology or differences were found between the exposed children and healthy controls. Only three children exposed to ustekinumab and two exposed to vedolizumab had lower total IgA antibody levels, but no severe IgA hypogammaglobulinemia was observed. Similar findings were observed in a recent study from Canada, which primarily evaluated the safety of the rotavirus vaccine in children exposed to biologics in utero. Amongst 191 children exposed to biologic treatment, no clinically significant abnormalities in lymphocyte subsets, quantitative immunoglobulins, or mitogen responses were identified. Similarly, no severe adverse events were reported after rotavirus vaccine administration [17].

Our study has several limitations. The biggest limitation is the small sample size, which precludes us from drawing firm conclusions. Slightly more than half of the women refused to participate mainly because they considered vein puncture too invasive for their children. Nevertheless, to date, it is still the largest documented cohort focused on the efficacy of vaccination in children exposed to ustekinumab or vedolizumab in utero. The small sample size also limited us from conducting further analyses, for example, regarding the impact of cord plasma levels or concomitant maternal immunosuppression. The other limitation is the different ages of the exposed and control groups at blood sampling (median age 25 vs. 37 months, respectively), despite our intention to include a control group of similar age to the exposed group. Thus, the theoretical impact of this difference on the serologic results cannot be excluded.

In conclusion, our research contributes valuable data to the limited body of knowledge regarding the effects of in utero exposure to ustekinumab and vedolizumab on children’s immune responses. Although our study was limited by its sample size, the findings suggest no major adverse effects on vaccine responses or overall immunological health in these children. This information is pivotal for guiding treatment decisions in pregnant women with IBD, and for a broader field of clinical immunology.

Supplementary information

ESM 1 (PNG 331 kb)Supplementary Figure 1. Flowchart of children recruitment. *two children were born to one woman

High Resolution Image (TIFF 97 kb)

ESM 2 (DOCX 15 kb)

ESM 3 (DOCX 14 kb)

Abbreviations

ELISA Enzyme-linked immunosorbent assay

Hib Haemophilus influenzae B

IBD Inflammatory bowel disease

Ig Immunoglobulin

UST Ustekinumab

TNF Tumour necrosis factor

VDZ Vedolizumab

Acknowledgements

We are grateful to all the children and their parents, and to all co-workers who were part of the study, especially Marie Barabasova and Ondrej Hradsky.

Authors’ contributions

The authors confirm their contribution to the paper as follows: study conception and design: DD, KM, KC; data collection: KM, KZ, BP, DD, JS, PM, MA, JD, ML; analysis and interpretation of results: DD, KM, KC; draft manuscript preparation: KM, DD, KC. All authors reviewed the results and approved the final version of the manuscript.

Funding

Open access publishing supported by the National Technical Library in Prague. This work was supported by the Ministry of Health, Czech Republic, for the conceptual development of the research organisations (00064203, University Hospital Motol, Prague, Czech Republic), and by the IBD-Comfort Foundation.

Data availability

The data underlying this article will be shared upon reasonable request by the corresponding author.

Declarations

Ethics approval

This study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Ethical Committee of the IBD Clinical and Research Center, ISCARE (No. 2022/IIIa).

Consent to participate

Written informed consent was obtained from the parents.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Torres J Chaparro M Julsgaard M European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation J Crohns Colitis 2023 17 1 1 27 10.1093/ecco-jcc/jjac115 36005814
Torres J, Chaparro M, Julsgaard M et al (2023) European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis 17(1):1–27. 10.1093/ecco-jcc/jjac11536005814
2. Wieringa JW van der Woude CJ Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease Best Pract Res Clin Gastroenterol 2020 44–45 101665 10.1016/j.bpg.2019.101665 32359679
Wieringa JW, van der Woude CJ (2020) Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol 44–45:101665. 10.1016/j.bpg.2019.10166532359679
3. Duricova D Dvorakova E Hradsky O Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation Inflamm Bowel Dis 2019 25 4 789 796 10.1093/ibd/izy294 30239799
Duricova D, Dvorakova E, Hradsky O et al (2019) Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation. Inflamm Bowel Dis 25(4):789–796. 10.1093/ibd/izy29430239799
4. Beaulieu DB Ananthakrishnan AN Martin C Cohen RD Kane SV Mahadevan U Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2018 16 1 99 105 10.1016/j.cgh.2017.08.041
Beaulieu DB, Ananthakrishnan AN, Martin C, Cohen RD, Kane SV, Mahadevan U (2018) Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 16(1):99–105. 10.1016/j.cgh.2017.08.041
5. de Lima A Kanis SL Escher JC van der Woude CJ Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero J Crohns Colitis 2018 12 8 948 953 10.1093/ecco-jcc/jjy053 29726943
de Lima A, Kanis SL, Escher JC, van der Woude CJ (2018) Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero. J Crohns Colitis 12(8):948–953. 10.1093/ecco-jcc/jjy05329726943
6. Gisbert JP Chaparro M Vaccines in children exposed to biological agents in utero and/or during breastfeeding: are they effective and safe? J Crohns Colitis 2023 17 6 995 1009 10.1093/ecco-jcc/jjad005 36652274
Gisbert JP, Chaparro M (2023) Vaccines in children exposed to biological agents in utero and/or during breastfeeding: are they effective and safe? J Crohns Colitis 17(6):995–1009. 10.1093/ecco-jcc/jjad00536652274
7. Wyant T Leach T Sankoh S Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results Gut 2015 64 1 77 83 10.1136/gutjnl-2014-307127 24763133
Wyant T, Leach T, Sankoh S et al (2015) Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut 64(1):77–83. 10.1136/gutjnl-2014-30712724763133
8. Brodmerkel C Wadman E Langley RG Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use J Drugs Dermatol JDD 2013 12 10 1122 1129 24085047
Brodmerkel C, Wadman E, Langley RG et al (2013) Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use. J Drugs Dermatol JDD 12(10):1122–112924085047
9. Haykir Solay A Eser F High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study Hum Vaccines Immunother 2019 15 5 1177 1182 10.1080/21645515.2019.1574151
Haykir Solay A, Eser F (2019) High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: a pilot study. Hum Vaccines Immunother 15(5):1177–1182. 10.1080/21645515.2019.1574151
10. Mitrova K Pipek B Bortlik M Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study J Crohns Colitis 2022 16 12 1808 1815 10.1093/ecco-jcc/jjac086 35708729
Mitrova K, Pipek B, Bortlik M et al (2022) Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study. J Crohns Colitis 16(12):1808–1815. 10.1093/ecco-jcc/jjac08635708729
11. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByCountry?SelectedCountryId=201&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=false. Accessed 2 Jul 2024
12. Pittet LF Verolet CM Michetti P High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease Am J Gastroenterol 2019 114 7 1130 1141 10.14309/ajg.0000000000000289 31205131
Pittet LF, Verolet CM, Michetti P et al (2019) High immunogenicity of the pneumococcal conjugated vaccine in immunocompromised adults with inflammatory bowel disease. Am J Gastroenterol 114(7):1130–1141. 10.14309/ajg.000000000000028931205131
13. Moses J Alkhouri N Shannon A Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab Am J Gastroenterol 2012 107 1 133 138 10.1038/ajg.2011.295 21876562
Moses J, Alkhouri N, Shannon A et al (2012) Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 107(1):133–138. 10.1038/ajg.2011.29521876562
14. Nguyen DL Nguyen ET Bechtold ML Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis Dig Dis Sci 2015 60 8 2446 2453 10.1007/s10620-015-3631-y 25796579
Nguyen DL, Nguyen ET, Bechtold ML (2015) Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci 60(8):2446–2453. 10.1007/s10620-015-3631-y25796579
15. Gisbert JP Villagrasa JR Rodríguez-Nogueiras A Chaparro M Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease Am J Gastroenterol 2012 107 10 1460 1466 10.1038/ajg.2012.79 23034605
Gisbert JP, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M (2012) Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 107(10):1460–1466. 10.1038/ajg.2012.7923034605
16. Jiang HY Wang SY Deng M Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis Vaccine 2017 35 20 2633 2641 10.1016/j.vaccine.2017.03.080 28404358
Jiang HY, Wang SY, Deng M et al (2017) Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine 35(20):2633–2641. 10.1016/j.vaccine.2017.03.08028404358
17. Fitzpatrick T Alsager K Sadarangani M Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network Lancet Child Adolesc Health 2023 7 9 648 656 10.1016/S2352-4642(23)00136-0 37390832
Fitzpatrick T, Alsager K, Sadarangani M et al (2023) Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. Lancet Child Adolesc Health 7(9):648–656. 10.1016/S2352-4642(23)00136-037390832
18. Moens A van der Woude CJ Julsgaard M Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study Aliment Pharmacol Ther 2020 51 1 129 138 10.1111/apt.15539 31692017
Moens A, van der Woude CJ, Julsgaard M et al (2020) Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther 51(1):129–138. 10.1111/apt.1553931692017
19. Rowan CR Cullen G Mulcahy HE Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation J Crohns Colitis 2018 12 3 376 378 10.1093/ecco-jcc/jjx141 29045603
Rowan CR, Cullen G, Mulcahy HE et al (2018) Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohns Colitis 12(3):376–378. 10.1093/ecco-jcc/jjx14129045603
20. Klenske E Osaba L Nagore D Rath T Neurath MF Atreya R Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn’s disease J Crohns Colitis 2019 13 2 267 269 10.1093/ecco-jcc/jjy153 30388211
Klenske E, Osaba L, Nagore D, Rath T, Neurath MF, Atreya R (2019) Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn’s disease. J Crohns Colitis 13(2):267–269. 10.1093/ecco-jcc/jjy15330388211
21. Mitrova K Pipek B Bortlik M Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study Ther Adv Gastroenterol 2021 14 17562848211032790 10.1177/17562848211032790
Mitrova K, Pipek B, Bortlik M et al (2021) Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study. Ther Adv Gastroenterol 14:17562848211032790. 10.1177/17562848211032790
22. Saito J Kaneko K Kawasaki H Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum J Pharm Health Care Sci 2022 8 1 18 10.1186/s40780-022-00249-8 35773736
Saito J, Kaneko K, Kawasaki H et al (2022) Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum. J Pharm Health Care Sci 8(1):18. 10.1186/s40780-022-00249-835773736
23. Mahadevan U Long MD Kane SV Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease Gastroenterology 2021 160 4 1131 1139 10.1053/j.gastro.2020.11.038 33227283
Mahadevan U, Long MD, Kane SV et al (2021) Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology 160(4):1131–1139. 10.1053/j.gastro.2020.11.03833227283
24. Julsgaard M Baumgart DC Baunwall SMD Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study Aliment Pharmacol Ther 2021 54 10 1320 1329 10.1111/apt.16593 34472644
Julsgaard M, Baumgart DC, Baunwall SMD et al (2021) Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther 54(10):1320–1329. 10.1111/apt.1659334472644
25. Flanagan E Gibson PR Wright EK Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure Aliment Pharmacol Ther 2020 52 10 1551 1562 10.1111/apt.16102 32981127
Flanagan E, Gibson PR, Wright EK et al (2020) Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther 52(10):1551–1562. 10.1111/apt.1610232981127
26. Flanagan E Prentice R Wright EK Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero Aliment Pharmacol Ther 2022 55 6 700 704 10.1111/apt.16739 34907546
Flanagan E, Prentice R, Wright EK et al (2022) Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. Aliment Pharmacol Ther 55(6):700–704. 10.1111/apt.1673934907546
27. Wieringa JW van Beek RHT Rövekamp LW Driessen GJA van Wering HM Response to vaccination in infants exposed to antitumor necrosis factor alpha in utero Pediatr Infect Dis J 2021 40 10 912 916 10.1097/INF.0000000000003271 34260494
Wieringa JW, van Beek RHT, Rövekamp LW, Driessen GJA, van Wering HM (2021) Response to vaccination in infants exposed to antitumor necrosis factor alpha in utero. Pediatr Infect Dis J 40(10):912–916. 10.1097/INF.000000000000327134260494
28. Sheibani S Cohen R Kane S Dubinsky M Church JA Mahadevan U The effect of maternal peripartum anti-TNFα use on infant immune response Dig Dis Sci 2016 61 6 1622 1627 10.1007/s10620-015-3992-2 26725061
Sheibani S, Cohen R, Kane S, Dubinsky M, Church JA, Mahadevan U (2016) The effect of maternal peripartum anti-TNFα use on infant immune response. Dig Dis Sci 61(6):1622–1627. 10.1007/s10620-015-3992-226725061
29. Hefele L Lai J Vilivong K Haemophilus influenzae serotype b seroprevalence in central Lao PDR before and after vaccine introduction PLoS ONE 2022 17 9 e0274558 10.1371/journal.pone.0274558 36107979
Hefele L, Lai J, Vilivong K et al (2022) Haemophilus influenzae serotype b seroprevalence in central Lao PDR before and after vaccine introduction. PLoS ONE 17(9):e0274558. 10.1371/journal.pone.027455836107979
30. Zinke M Disselhoff J DTP a-HBV-IPV-110 and -111 study groupsGartner B Jacquet JM Immunological persistence in 4–6 and 7–9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib Hum Vaccin 2010 6 2 189 193 10.4161/hv.6.2.10117 20009522
Zinke M, Disselhoff J, DTP a-HBV-IPV-110 and -111 study groups, Gartner B, Jacquet JM (2010) Immunological persistence in 4–6 and 7–9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib. Hum Vaccin 6(2):189–193. 10.4161/hv.6.2.1011720009522
